Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RGT-419B in Advanced Breast Cancer and Solid Tumors
NCT06299124Phase 1Active, not recruiting
- Sponsor
- Regor Therapeutics
- Start
- Apr 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GDC-4198 in breast cancer and solid tumor, sponsored by Regor Therapeutics. Primary endpoint: Dose-Limiting Toxicities at 4 weeks. Started Apr 2023; status: active, not recruiting.
02
Drugs
GDC-4198
03
Conditions
breast cancersolid tumor
Beyond the preview
Go deeper on NCT06299124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06299124.